STUDY TYPE: Aetiology (inception cohort) Level of Evidence 2b. OBJECTIVE: To determine whether there might be differences in bone mineral content (BMC) between men who develop life-threatening prostate cancer and those who do not, as bone is a common site of prostate cancer metastases. SUBJECTS AND METHODS: From 1973 to 1984, BMC was serially measured in 519 participants (778 observations) as part of a longitudinal study of ageing. We examined the association between serial BMC measurements with the development of overall and high-risk prostate cancer over the next one to three decades. For all prostate cancer cases, BMC was censored at the time of diagnosis. RESULTS: During a median (range) overall follow-up of 21.1 (0.2-35.0) years after the last BMC measurement, 76 (14.6%) men were later diagnosed with prostate cancer (18 high-risk and 58 not high-risk). BMC declined with age to a greater extent in healthy controls than among men diagnosed with prostate cancer (P = 0.018, likelihood ratio test), and tended to decline less in high-risk than non-high-risk cases. CONCLUSION: The distribution of BMC was significantly different between men who did and did not develop prostate cancer, over an extended follow-up. Specifically, BMC appeared to decline to a greater extent with age among healthy controls than in men with prostate cancer, especially high-risk disease. The biology underlying the lesser decline in BMC among men with prostate cancer remains unclear, but suggests that host factors in the bony milieu might be associated with prostate cancer development and progression.
STUDY TYPE: Aetiology (inception cohort) Level of Evidence 2b. OBJECTIVE: To determine whether there might be differences in bone mineral content (BMC) between men who develop life-threatening prostate cancer and those who do not, as bone is a common site of prostate cancer metastases. SUBJECTS AND METHODS: From 1973 to 1984, BMC was serially measured in 519 participants (778 observations) as part of a longitudinal study of ageing. We examined the association between serial BMC measurements with the development of overall and high-risk prostate cancer over the next one to three decades. For all prostate cancer cases, BMC was censored at the time of diagnosis. RESULTS: During a median (range) overall follow-up of 21.1 (0.2-35.0) years after the last BMC measurement, 76 (14.6%) men were later diagnosed with prostate cancer (18 high-risk and 58 not high-risk). BMC declined with age to a greater extent in healthy controls than among men diagnosed with prostate cancer (P = 0.018, likelihood ratio test), and tended to decline less in high-risk than non-high-risk cases. CONCLUSION: The distribution of BMC was significantly different between men who did and did not develop prostate cancer, over an extended follow-up. Specifically, BMC appeared to decline to a greater extent with age among healthy controls than in men with prostate cancer, especially high-risk disease. The biology underlying the lesser decline in BMC among men with prostate cancer remains unclear, but suggests that host factors in the bony milieu might be associated with prostate cancer development and progression.
Authors: Clareann H Bunker; Joseph M Zmuda; Alan L Patrick; Victor W Wheeler; Joel L Weissfeld; Lewis H Kuller; Jane A Cauley Journal: Cancer Causes Control Date: 2006-10 Impact factor: 2.506
Authors: Sonja I Berndt; H Ballentine Carter; Patricia K Landis; Katherine L Tucker; Lillian J Hsieh; E Jeffrey Metter; Elizabeth A Platz Journal: Urology Date: 2002-12 Impact factor: 2.649
Authors: Stephen J Freedland; Kelly A Grubb; Sindy K Yiu; Elizabeth B Humphreys; Matthew E Nielsen; Leslie A Mangold; William B Isaacs; Alan W Partin Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Yuqing Zhang; Douglas P Kiel; R Curtis Ellison; Arthur Schatzkin; Joanne F Dorgan; Bernard E Kreger; L Adrienne Cupples; David T Felson Journal: Am J Med Date: 2002-12-15 Impact factor: 4.965
Authors: Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key; Luigi Ferrucci; H Ballentine Carter; E Jeffrey Metter; Chu Chen; Noel S Weiss; Annette Fitzpatrick; Ann W Hsing; James V Lacey; Kathy Helzlsouer; Sabina Rinaldi; Elio Riboli; Rudolf Kaaks; Joop A M J L Janssen; Mark F Wildhagen; Fritz H Schröder; Elizabeth A Platz; Michael Pollak; Edward Giovannucci; Catherine Schaefer; Charles P Quesenberry; Joseph H Vogelman; Gianluca Severi; Dallas R English; Graham G Giles; Pär Stattin; Göran Hallmans; Mattias Johansson; June M Chan; Peter Gann; Steven E Oliver; Jeff M Holly; Jenny Donovan; François Meyer; Isabelle Bairati; Pilar Galan Journal: Ann Intern Med Date: 2008-10-07 Impact factor: 25.391